Fig. 3
From: Advances in immunotherapy for triple-negative breast cancer
The diagram of overcoming TNBC Immunotherapy Resistance. Pos3Aa-p53 also significantly enhances the sensitivity of p53- deficient TNBC cells to the chemotherapy drug, 5-fluorouracil, and increases IFN. The combination of the CXCR2 antagonist, AZD5069, with doxorubicin, has been found to inhibit doxorubicin-mediated CXCR2 overexpression and reduce chemoresistance and TGF-β expression in TNBC. PmTriTNE@CDA releases STING agonist CDA to upregulate the expression of IFN-γ, promote the maturation of DCs, and recruit CD4 + T cells, CD8 + T cells, and NK cells. CSCs are suppressed by PmTriTNE@CDA to recruit CD8 + T cells